Department of Clinical and Experimental Epilepsy, UCL, Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.
Brain. 2011 Oct;134(Pt 10):2969-81. doi: 10.1093/brain/awr209. Epub 2011 Sep 8.
The long-term pathological effects of chronic epilepsy on normal brain ageing are unknown. Previous clinical and epidemiological studies show progressive cognitive decline in subsets of patients and an increased prevalence of Alzheimer's disease in epilepsy. In a post-mortem series of 138 patients with long-term, mainly drug-resistant epilepsy, we carried out Braak staging for Alzheimer's disease neurofibrillary pathology using tau protein immunohistochemistry. The stages were compared with clinicopathological factors, including seizure history and presence of old traumatic brain injury. Overall, 31% of cases were Braak Stage 0, 36% Stage I/II, 31% Stage III/IV and 2% Stage V/VI. The mean age at death was 56.5 years and correlated with Braak stage (P < 0.001). Analysis of Braak stages within age groups showed a significant increase in mid-Braak stages (III/IV), in middle age (40-65 years) compared with data from an ageing non-epilepsy series (P < 0.01). There was no clear relationship between seizure type (generalized or complex partial), seizure frequency, age of onset and duration of epilepsy with Braak stage although higher Braak stages were noted with focal more than with generalized epilepsy syndromes (P < 0.01). In 30% of patients, there was pathological evidence of traumatic brain injury that was significantly associated with higher Braak stages (P < 0.001). Cerebrovascular disease present in 40.3% and cortical malformations in 11.3% were not significantly associated with Braak stage. Astrocytic-tau protein correlated with the presence of both traumatic brain injury (P < 0.01) and high Braak stage (P < 0.001). Hippocampal sclerosis, identified in 40% (bilateral in 48%), was not associated with higher Braak stages, but asymmetrical patterns of tau protein accumulation within the sclerotic hippocampus were noted. In over half of patients with cognitive decline, the Braak stage was low indicating causes other than Alzheimer's disease pathology. In summary, there is evidence of accelerated brain ageing in severe chronic epilepsy although progression to high Braak stages was infrequent. Traumatic brain injury, but not seizures, was associated with tau protein accumulation in this series. It is likely that Alzheimer's disease pathology is not the sole explanation for cognitive decline associated with epilepsy.
慢性癫痫对正常大脑老化的长期病理影响尚不清楚。以前的临床和流行病学研究表明,在一些患者亚群中存在认知能力逐渐下降,并且癫痫患者中阿尔茨海默病的发病率增加。在一项对 138 例长期、主要是耐药性癫痫患者的死后系列研究中,我们使用 Tau 蛋白免疫组织化学对阿尔茨海默病神经纤维病理学进行了 Braak 分期。将这些分期与临床病理因素进行了比较,包括癫痫发作史和陈旧性创伤性脑损伤的存在。总的来说,31%的病例为 Braak 0 期,36%为 I/II 期,31%为 III/IV 期,2%为 V/VI 期。死亡时的平均年龄为 56.5 岁,与 Braak 分期相关(P<0.001)。对年龄组内的 Braak 分期进行分析显示,与非癫痫性衰老系列数据相比,在中年(40-65 岁)时,中晚期(III/IV 期)明显增加(P<0.01)。尽管局灶性癫痫比全身性癫痫综合征的 Braak 分期更高,但癫痫发作类型(全面性或复杂部分性)、发作频率、发病年龄和癫痫持续时间与 Braak 分期之间无明显关系(P<0.01)。30%的患者有创伤性脑损伤的病理证据,这与更高的 Braak 分期显著相关(P<0.001)。40.3%的患者存在脑血管疾病,11.3%的患者存在皮质畸形,但与 Braak 分期无明显相关性。星形细胞 Tau 蛋白与创伤性脑损伤(P<0.01)和高 Braak 分期(P<0.001)均相关。40%(双侧 48%)的患者存在海马硬化,但与较高的 Braak 分期无关,但在硬化的海马内注意到 Tau 蛋白积累的不对称模式。在认知能力下降的患者中,超过一半的患者 Braak 分期较低,表明除了阿尔茨海默病病理学外,还有其他原因。总之,尽管进展到高 Braak 分期的情况并不常见,但严重的慢性癫痫确实存在加速的大脑老化的证据。在本系列中,创伤性脑损伤而非癫痫发作与 Tau 蛋白的积累有关。阿尔茨海默病病理学可能不是与癫痫相关的认知能力下降的唯一解释。